Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium Clinical research trials and A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium. A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium clinical trial. Participants typically obtain the most effective healthcare available for their A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium



A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

For Condition: Urologic Neoplasms,Metastases, Neoplasm
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
Details:
Eligibility:
Study Type:
  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body. - You must have at least one tumor that can be physically measured or scanned by x-ray. - You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago. Exclusion Criteria: - You may not have used an experimental medicine or device within the past month. - Cancer that has spread to your brain. - If you are unwilling or unable to take folic acid or vitamin B12 supplements.
Total Enrollment: 

Location and Contact Information:


Additional Information:
Study ID Numbers:
  4698; 
Study Start Date: 
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035061

Other Metastases, Neoplasm Studies:
1. A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

2. Phase I-II study to evaluate safety, efficacy and pharmacokinetic interactions between capecitabine (XELODA) and exisulind (APTOSYN) in patients with metastatic breast cancer.

3. Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent with Metastatic Lung Cancer

4. Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

5. An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.

Related Studies:

Other Metastases, Neoplasm Clinical Trials
Other Florida Clinical Trials
Other Tampa Clinical Trials

A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Modify your Search

  Other Metastases, Neoplasm Clinical Trials
  Other Florida Clinical Trials
  Other Tampa Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103